企業プロフィール
Entrada Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- TRDA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
7.57 USD (-0.39%)
終値
最終更新: 2026年8月21日
258M USD
時価総額
株価変動の要因
As of Aug 21, 2026, TRDA closed down 0.39% at $7.57. No new same-company headline was identified in the current news window.
企業概要
Intracellular Genetic Medicines
Entrada Therapeutics develops Endosomal Escape Vehicle therapeutics intended to deliver oligonucleotides into cells and engage previously inaccessible intracellular targets.
ENTR-601-44
ENTR-601-44 is an exon-skipping candidate for people with Duchenne muscular dystrophy amenable to exon 44 skipping.
ENTR-601-45
ENTR-601-45 applies the same intracellular-delivery platform to patients amenable to exon 45 skipping.
ELEVATE Clinical Program
The ELEVATE studies evaluate multiple ascending doses, safety, target engagement and early functional outcomes to guide further development of Entrada's Duchenne franchise.
今後のカタリスト
- ELEVATE-45-201 Cohort 1 data around mid-2026.
- ELEVATE-44-201 open-label-period and Cohort 2 data by year-end 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。